Intense Pulsed Light in Meibomian Gland Dysfunctions
LACRYSTIM
1 other identifier
observational
45
1 country
1
Brief Summary
Dry eye disease (DED) is an extremely common disease whose meibomian gland dysfunction is the main etiology. Polychromatic intense pulsed light (IPL) is a promising new therapeutic alternative but few clinical data have been published. A new IPL device has recently been marketed: LACRYSTIM (QUANTEL, France). The investigators have been using it in our clinical practice since June 2019. The investigators present a retrospective study on our first clinical results.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 25, 2019
CompletedStudy Start
First participant enrolled
October 25, 2019
CompletedFirst Posted
Study publicly available on registry
November 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2020
CompletedMay 13, 2022
October 1, 2019
7 months
October 25, 2019
May 12, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Lacrydiag in current clinical practice
The LacryDiag ocular surface analyzer is used for the diagnosis of dry eyes.
6 months
Secondary Outcomes (6)
collection of adverse events
6 months
Ocular Surface Disease Index questionnaire
6 months
Slit lamp Photography x16 and x25
6 months
Oxford Score
6 months
Break-up time Test
6 months
- +1 more secondary outcomes
Study Arms (1)
Patients with dry eye disease with meibomian gland dysfunction
Collected data from patient records for consultations Day 0, Day 15 and Day 45 (3 treatment sessions) and Months 3, Months 6 (follow-up consultations). \- parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
Interventions
collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
Eligibility Criteria
Patients with Dry eye disease with meibomian gland dysfunction, preferentially mild to moderate, and having benefited from intense pulsed light treatment
You may qualify if:
- Patients with Dry eye disease with meibomian gland dysfunction, preferentially mild to moderate, and having benefited from intense pulsed light treatment.
- patient affiliated with a social security organization
You may not qualify if:
- patient with incomplete follow-up
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Centre Hospitalier Universitaire de Saint Etiennelead
- Quantel Medicalcollaborator
Study Sites (1)
CHU de Saint Etienne
Saint-Etienne, 42055, France
Related Publications (1)
Trone MC, Garcin T, Ollier E, Thuret G, Gain P. A retrospective study of the efficacy of intense pulsed light delivered by the Lacrystim(R) for meibomian gland dysfunction therapy. BMC Ophthalmol. 2022 Aug 6;22(1):335. doi: 10.1186/s12886-022-02531-7.
PMID: 35933379DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marie Caroline TRONE, MD
CHU de Saint Etienne
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 25, 2019
First Posted
November 1, 2019
Study Start
October 25, 2019
Primary Completion
June 1, 2020
Study Completion
June 1, 2020
Last Updated
May 13, 2022
Record last verified: 2019-10
Data Sharing
- IPD Sharing
- Will not share